Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Defactinib - Verastem Oncology

Next Previous
Drug Profile

Defactinib - Verastem Oncology

Alternative Names: AVMAPKI FAKZYNJA CO-PACK; Defactinib hydrochloride; FAKZYNJA™; PF-04554878; PF-4554878; VS-6063

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Cancer Research UK; National Cancer Institute (USA); University of Utah; Verastem; Verastem Oncology
  • Class Amines; Antineoplastics; Benzamides; Fluorinated hydrocarbons; Pyrazines; Pyrimidines; Small molecules; Sulfones
  • Mechanism of Action Focal adhesion protein tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer; Pancreatic cancer; Mesothelioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ovarian cancer
  • Phase II Adenocarcinoma; Gynaecological cancer; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Solid tumours; Thyroid cancer; Uveal melanoma
  • Phase I/II Glioblastoma; Malignant melanoma
  • Discontinued Breast cancer; Cancer; Malignant-mesothelioma

Most Recent Events

  • 22 May 2025 Efficacy and adverse events data from a phase III RAMP 205 trial in Pancreatic cancer released by Verastem Oncology
  • 22 May 2025 Verastem Oncology plans a phase III trial for Pancreatic cancer (Late stage disease, Metastatic disease, First line therapy) in USA in 2026
  • 13 May 2025 Launched for Ovarian cancer (Recurrent, Second-line therapy or greater, Combination therapy) in USA (PO) - First global launch

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top